PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.

doi:10.1080/14728222.2021.2018418

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.

Expert opinion on therapeutic targets - 1 Dec 2021

Cherubini Alessandro, Casirati Elia, Tomasi Melissa, Valenti Luca

Abstract excerpt

INTRODUCTION: An interaction between metabolic triggers and inherited predisposition underpins the development and progression of non alcoholic fatty liver disease (NAFLD) and fatty liver disease in general. Among the specific NAFLD risk variants, PNPLA3 rs738409 C>G, encoding for the p.I148M protein variant, accounts for the largest fraction of liver disease heritability and is being intensively scrutinized. It...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Lipase

Share to Liver

Share to Liver Disease Diagnosis and Treatment

Share to Membrane Proteins

Share to Non-alcoholic Fatty Liver Disease

Share to Polymorphism, Single Nucleotide

Source

Open in PubMed

Identifiers

PMID: 34904923
DOI: 10.1080/14728222.2021.2018418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.PMID 34904923Read ↗

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.Semantic proximity Read ↗

PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease.Semantic proximity Read ↗

[The role of the PNPLA3 gene rs738409 variant in the spectrum of metabolic dysfunction associated steatotic liver diseases].Semantic proximity Read ↗

PNPLA3—A Potential Therapeutic Target for Personalized Treatment of Chronic Liver DiseaseSemantic proximity Read ↗

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.Semantic proximity Read ↗

PNPLA3 in Alcohol-Related Liver Disease.Semantic proximity Read ↗

Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein.Semantic proximity Read ↗

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Semantic proximity Read ↗

Research progress, challenges and perspectives on PNPLA3 and its variants in Liver DiseasesSemantic proximity Read ↗

PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver diseaseSemantic proximity Read ↗

Fifteen Years of PNPLA3: Transforming Hepatology Through Human Genetics.Semantic proximity Read ↗

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.